news

 Mar 21, 2023, 16:30 ET  CUPERTINO, Calif., March 21, 2023 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that Gail Maderis has assumed the role of Chair of the Board of DURECT effective March 17, 2023.  Ms. Maderis succeeds David Hoffmann as Chair of the Board. Mr. Hoffman has decided not to stand for re-election …

DURECT Corporation Announces Appointment of Gail Maderis as Chair of the Board Read More »

 Mar 09, 2023, 08:30 ET  CUPERTINO, Calif., March 9, 2023 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James Brown, President and CEO and additional members of the management team will participate in a fireside chat hosted by Francois Brisebois, Managing Director, Senior Biotechnology Research Analyst at Oppenheimer & Co. Inc. at the …

DURECT Corporation Fireside Chat at the Oppenheimer 33rd Annual Healthcare Conference Read More »

 Mar 07, 2023, 16:05 ET  –  Webcast of Earnings Call Today, March 7th at 4:30 p.m. ET –  Topline data from AHFIRM trial expected in 2023 CUPERTINO, Calif., March 7, 2023 /PRNewswire / — DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months and year ended December 31, 2022 and provided a …

DURECT Corporation Reports Fourth Quarter and Full Year 2022 Financial Results and AHFIRM Trial Update Read More »

 Feb 28, 2023, 18:07 ET  CUPERTINO, Calif., Feb. 28, 2023 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that it will report its fourth quarter and full year 2022 financial results and host a conference call after the market close on Tuesday, March 7, 2023. Tuesday, March 7 @ 4:30pm Eastern Time / 1:30pm Pacific …

DURECT Corporation to Announce Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 7 Read More »

 Feb 03, 2023, 17:17 ET  CUPERTINO, Calif., Feb. 3, 2023 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) (“DURECT”), a biopharmaceutical company focused on developing its epigenetic regulator program for the treatment of acute organ injury and chronic liver diseases, today announced that it has entered into a definitive agreement with a leading institutional healthcare investor and …

DURECT Corporation Announces $10 Million Registered Direct Offering of Common Stock and Warrants Read More »

 Nov 28, 2022, 18:46 ET  CUPERTINO, Calif., Nov. 28, 2022 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company focused on developing epigenetic regulator programs for the treatment of acute organ injury and chronic liver diseases, announced that DURECT’s board of directors today determined that the Company will effect a reverse stock split at a …

DURECT Announces 1-for-10 Reverse Stock Split Read More »

 Nov 02, 2022, 16:05 ET  –  Webcast of Earnings Call Today, November 2nd at 4:30 p.m. ET –  AHFIRM trial timeline continues to improve CUPERTINO, Calif., Nov. 2, 2022 /PRNewswire / — DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended September 30, 2022 and provided a corporate update. “We are …

DURECT Corporation Reports Third Quarter 2022 Financial Results and Update of Programs Read More »

 Oct 26, 2022, 08:30 ET  CUPERTINO, Calif., Oct. 26, 2022 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that it will report its third quarter 2022 financial results and host a conference call after the market close on Wednesday, November 2, 2022. Wednesday, November 2 @ 4:30pm Eastern Time / 1:30pm Pacific Time Toll Free: …

DURECT Corporation to Announce Third Quarter 2022 Financial Results and Provide Business Update on November 2 Read More »

 Oct 06, 2022, 08:30 ET  AHFIRM enrollment surpasses 200 of the planned 300 AH patients Enrollment completion now anticipated in Q2 2023 CUPERTINO, Calif., Oct. 6, 2022 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company focused on developing epigenetic regulator programs for the treatment of acute organ injury and chronic liver diseases, today announced …

DURECT Reaches Enrollment Milestone in Phase 2b AHFIRM Trial Read More »

 Sep 26, 2022, 08:30 ET  POSIMIR® is now commercially available in the U.S. for the treatment of post-surgical pain in adults following arthroscopic subacromial decompression surgery DURECT recently received an $8 million milestone payment for a new patent issuance and has now earned a $2 million milestone payment for first commercial sale of POSIMIR ATHLONE, …

Innocoll and DURECT Announce U.S. launch of POSIMIR® Read More »